Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PER® designates this enduring material for a maximum of 25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 25.0 Contact Hours.


PER Pulse™ Recaps highlight key elements of the 14th Annual School of Breast Oncology® Online CME Activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas; AstraZeneca; Celgene Corporation; Eisai; Genentech; Genomic Health, Inc; Lilly; Medivation, Inc; Merck Sharp & Dohme Corp; and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding visit

14th Annual School of Breast Oncology® Online

Release Date: February 10, 2017
Expiration Date: February 10, 2018
Media: Internet - based

Repurposing Statement

If you previously attended and received credit for the live CME/CE-certified conference, 14th Annual School of Breast Oncology®, which was held November 3-5, 2016, in Atlanta, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will Physicians’ Education Resource®, LLC (PER®), award, duplicate credit for the activity.

Activity Overview

An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators. Not only does the School of Breast Oncology® provide a comprehensive overview for fellows or oncologists who are new to practice, it also serves as a valuable refresher course with updates on the latest data and changes to standards of care for the oncologist who has been in practice for several years or more. This online activity captures all of the lectures presented at the live 2016 School of Breast Oncology®, organizes them in a convenient modular format, and summarizes the existing data for each topic with an emphasis on the evidence-based foundations for optimal, individualized decision making in the clinic.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas; AstraZeneca; Celgene Corporation; Eisai; Genentech; Genomic Health, Inc; Lilly; Medivation, Inc; Merck Sharp & Dohme Corp; and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding visit

CME/CE Activity Table of Contents

  • Module 1: Breast Carcinogenesis & Management of High-Risk Disease
  • Module 2: Breast Imaging
  • Module 3: Pathology and Biomarkers
  • Module 4: Breast Surgery
  • Module 5: Breast Radiation Therapy
  • Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy
  • Module 7: Treatment of HER2-Positive Disease
  • Module 8: Systemic Treatment of Advanced/Metastatic Disease
  • Module 9: Organ-Targeted Treatment of Metastatic Disease
  • Module 10: Toxicity Management and Survivorship Considerations

Instructions for Receiving Credit

In order to receive a CME/CE certificate, participants must complete the pretest, view any number of the 10 slide modules, and complete the posttest (with a passing score of 70% or higher), evaluation, and request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:
  • Review breast cancer pathology, tumor biology, and prognostic/predictive markers in order to stratify risk among patients with breast cancer
  • Discuss currently accepted diagnostic standards and imaging modalities for breast cancer
  • Integrate biomarkers, molecular assays, and other risk assessment tools into clinical practice to optimize clinical decision making for patients with breast cancer
  • Describe current treatment standards concerning the use of surgical, radiation, and medical therapies for patients with breast cancer
  • Describe strategies for the management of early stage or locally advanced breast cancer
  • Review methods to individualize the application of systemic therapies for patients with advanced breast cancer
  • Discuss strategies to proactively mitigate predictable treatment-related toxicities to optimize outcomes for patients with breast cancer
  • Determine recent practice-changing results from clinical trials and facilitate discussions with patients concerning their eligibility for clinical trial opportunities

Program Director

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
Co-Chair, Breast Cancer Research Program,
The US Oncology Network
Dallas, TX

Curriculum Development Committee

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Feinberg School of Medicine
Northwestern University
Chicago, IL

Frankie Ann Holmes, MD, FACP
Associate Director, Breast Oncology Research
Texas Oncology
Houston, TX

Eleftherios Mamounas, MD, MPH, FACS
Medical Director
Comprehensive Breast Program
UF Health Cancer Center -- Orlando Health
Orlando, FL

Anne Moore, MD
Medical Director, Weill Cornell Breast Center
Weill Cornell Medical College
New York, NY

Lori J. Pierce, MD, FASTRO
Professor of Radiation Oncology
University of Michigan School of Medicine
Vice Provost for Academic and Faculty Affairs
University of Michigan
Ann Arbor, MI

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


Carey K. Anders, MD
Assistant Professor of Medicine
Division of Hematology Oncology
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Douglas W. Arthur, MD
Professor and Vice-Chairman
Natalie N. and John R. Congdon, Sr. Endowed Chair of Cancer Research
Department of Radiation Oncology
Virginia Commonwealth University School of Medicine
Massey Cancer Center
Richmond, VA

David M. Euhus, MD, FACS
Professor (PAR) of Surgery
Chief, Breast Surgery Section
Division of Surgical Oncology
Johns Hopkins Hospital
Baltimore, MD

Carol Fabian, MD
Morris Family Endowed Chair in Cancer Prevention
Director, Breast Cancer Prevention and Survivorship Centers
Professor of Medicine
Division of Clinical Oncology
The University of Kansas Medical Center
Westwood, KS

Karin Hahn MD, MSc, MPH
Senior Medical Director (Oncology)
Associate Professor, Dept. of Oncology
University of Western Ontario
London Regional Cancer Program
Ontario, Canada

Syed A. Hoda, MD
Professor of Pathology
Weill Medical College of Cornell University
Attending Pathologist
New York-Presbyterian Hospital
New York, NY

Claudine Isaacs, MD
Medical Director, Fisher Center for Familial Cancer Research
Co-Director, Breast Cancer Program
Georgetown University
Washington, DC

Henry Kuerer, MD, PhD, FACS
Professor of Surgery and Director, Breast Surgical Oncology Training Program
Medical Director, Clinical Expansion, MD Anderson Cancer Network
University of Texas MD Anderson Cancer Center
Houston, TX

Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
Mayo Clinic
Rochester, MN

Anne McTiernan, MD, PhD
Research Professor, Epidemiology
Fred Hutchinson Cancer Research Center
Seattle, WA

Ruth O'Regan, MD
Chief, Division of Hematology/Oncology
University of Wisconsin
Carbone Cancer Center
Madison, WI

Soonmyung Paik, MD
National Surgical Adjuvant Breast and Bowel Project
Division of Pathology
Pittsburgh, PA

Debra Patt, MD MPH, MBA
Vice President, Texas Oncology
Medical Director, The US Oncology Network
Chair, Clinical Practice Committee ASCO
Editor and Chief- Journal of Clinical Oncology-Clinical Cancer Informatics
Austin, TX

Elizabeth Rafferty, MD
Staff Radiologist
Avon Comprehensive Breast Center
Massachusetts General Hospital
Boston, MA

Edward H. Romond, MD
Professor of Medicine
Division of Medical Oncology
Markey Cancer Center
University of Kentucky
Lexington, KY

Hani Sbitany, MD
Assistant Professor of Surgery
Division of Plastic and Reconstructive Surgery
University of California, San Francisco
San Francisco, CA

David M. Schuster, MD
Associate Professor
Director, Division of Nuclear Medicine and Molecular Imaging
Department of Radiology and Imaging Sciences
Emory University Hospital
Atlanta, GA

Lawrence J. Solin, MD, FACR, FASTRO
Chairman, Department of Radiation Oncology
Albert Einstein Healthcare Network
Philadelphia, PA

Joseph Sparano, MD
Professor of Medicine
Professor of Obstetrics, Gynecology, and Women’s Health
Albert Einstein College of Medicine
Associate Chairman
Department of Oncology
Montefiore Medical Center
Bronx, NY

Catherine Van Poznak, MD
Associate Professor
Division of Hematology Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, MI

Jeffrey N. Weitzel, MD
Professor of Oncology and Population Sciences
Chief, Division of Clinical Cancer Genetics
City of Hope Cancer Center
Duarte, CA

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose:

Douglas W. Arthur, MD; David Euhus, MD, FACS; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH; Syed A. Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne Moore, MD; Soonmyung Paik, MD; Debra Patt, MD, MPH, MBA; Edward H. Romond, MD; Jeffrey N. Weitzel, MD.

The staff of Physicians’ Education Resource®, LLC.

The following individuals have relevant financial relationships with commercial interests to disclose:

Carey K. Anders, MD – Consultant: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Lilly, Genentech, Nektar Therapeutics, Kadmon Corporation; Research Funding: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Puma Biotechnology, Lilly, Kadmon Corporation – all uncompensated; Carol Fabian, MD - Grant/Research Support: No monetary grants other than BCRF and Komen. Institution Receives Duavee from Pfizer for a clinical prevention trial and omega-3 fatty acids and placebo from DSM for a clinical trial; Other: DSM provides study agent (DHA and placebo) for clinical trial; Claudine Isaacs, MD – Grant/Research Support: Tesaro, Pfizer; Consultant: Pfizer, AstraZeneca; Speaker’s Bureau: Genentech, Pfizer; Henry M. Kuerer, MD, PhD, FACS – Grant/Research Support: Genomic Health; Consultant: Gerson Lehrman Group; Other: Editor, NEJM Medical Group and McGraw- Hill Publishing; Charles Loprinzi, MD – Grant/Research Support: Bristol-Myers Squibb, Pfizer, Janssen; Consultant: Cubist Pharmaceuticals, Mitsubishi Tanabe Pharma, Coronado Biosciences Inc, Lpath, Mundipharma, PledPharma; Eleftherios Mamounas, MD, MPH, FACS – Consultant: Genomic Health Inc, Genentech, Pfizer, Novartis, Biotheranostics, Bayer, GRAIL, Cellcuity; Speaker’s Bureau: Genomic Health, Roche/Genentech; Anne McTiernan, MD, PhD – Consultant: Pro-Change Behavior Systems, Inc; Shareholder: Merck (husband); Ruth O’Regan, MD – Grant/Research Support: Eisai, Pfizer, Novartis; Consultant: Pfizer, Lilly, Biotheranostics; Joyce O’Shaughnessy, MD – Advisory Board/Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept, Eisai, Genentech, GSK, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion; Lori J. Pierce, MD, FASTRO – Shareholder: PFS Genomics (founder's shares); Other: UpToDate (Royalties); Elizabeth Rafferty, MD – Grant/Research Support: Hologic, Inc, Investigation of tomosynthesis; Hope S. Rugo, MD – Grant/Research Support: GSK, Genentech/Roche, Merck, Novartis, Plexxikon, Eisai, OBI, Amgen, Pfizer, Macrogenics, Lilly; Speaker’s Bureau: Genomic Health; Hani Sbitany, MD – Consultant: LifeCell, Inc; David M. Schuster, MD - Grant/Research Support: Blue Earth Diagnostics Ltd, Nihon Medi-Physics Co Ltd (through Emory Office of Sponsored Projects); Consultant: American Imaging Management; Lawrence J. Solin, MD, FACR, FASTRO – Other: (not paid) Member, Advisory Board, GHI; Joseph Sparano, MD – AstraZeneca, Novartis, Celgene Corporation, Genentech/Roche, Lilly, Celldex Therapeutics; Catherine Van Poznak, MD – Grant/Research Support: Bayer; Other: Novartis (uncompensated) phase IV study steering committee.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for CE purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, and management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER ®or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Provider Contact Information

For questions about this CME activity, please contact:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Tel: (609) 378-3701
Fax: (609) 257-0705

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By